Subtype-specific overexpression of the Rac-GEF P-REX1 in breast cancer is associated with promoter hypomethylation
Open Access
- 24 September 2014
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research
- Vol. 16 (5) , 441
Abstract
Introduction: The Rac-GEF P-REX1 is a key mediator of ErbB signaling in breast cancer recently implicated in mammary tumorigenesis and metastatic dissemination. Although P-REX1 is essentially undetectable in normal human mammary epithelial tissue, this Rac-GEF is markedly upregulated in human breast carcinomas, particularly of the luminal subtype. The mechanisms underlying P-REX1 upregulation in breast cancer are unknown. Toward the goal of dissecting the mechanistic basis of P-REX1 overexpression in breast cancer, in this study we focused on the analysis of methylation of the PREX1 gene promoter. Methods: To determine the methylation status of the PREX1 promoter region, we used bisulfite genomic sequencing and pyrosequencing approaches. Re-expression studies in cell lines were carried out by treatment of breast cancer cells with the demethylating agent 5-aza-2′-deoxycitidine. PREX1 gene methylation in different human breast cancer subtypes was analyzed from the TCGA database. Results: We found that the human PREX1 gene promoter has a CpG island located between -1.2 kb and +1.4 kb, and that DNA methylation in this region inversely correlates with P-REX1 expression in human breast cancer cell lines. A comprehensive analysis of human breast cancer cell lines and tumors revealed significant hypomethylation of the PREX1 promoter in ER-positive, luminal subtype, whereas hypermethylation occurs in basal-like breast cancer. Treatment of normal MCF-10A or basal-like cancer cells, MDA-MB-231 with the demethylating agent 5-aza-2′-deoxycitidine in combination with the histone deacetylase inhibitor trichostatin A restores P-REX1 levels to those observed in luminal breast cancer cell lines, suggesting that aberrant expression of P-REX1 in luminal breast cancer is a consequence of PREX1 promoter demethylation. Unlike PREX1, the pro-metastatic Rho/Rac-GEF, VAV3, is not regulated by methylation. Notably, PREX1 gene promoter hypomethylation is a prognostic marker of poor patient survival. Conclusions: Our study identified for the first time gene promoter hypomethylation as a distinctive subtype-specific mechanism for controlling the expression of a key regulator of Rac-mediated motility and metastasis in breast cancer.Keywords
This publication has 86 references indexed in Scilit:
- MYC Deregulation in Gastric Cancer and Its Clinicopathological ImplicationsPLOS ONE, 2013
- Exome sequencing identifies recurrent somatic RAC1 mutations in melanomaNature Genetics, 2012
- A Landscape of Driver Mutations in MelanomaCell, 2012
- Rac signaling in breast cancer: A tale of GEFs and GAPsCellular Signalling, 2012
- P-Rex1 is required for efficient melanoblast migration and melanoma metastasisNature Communications, 2011
- Identification of the Rac-GEF P-Rex1 as an Essential Mediator of ErbB Signaling in Breast CancerMolecular Cell, 2010
- Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: A children's oncology group studyPediatric Blood & Cancer, 2010
- A collection of breast cancer cell lines for the study of functionally distinct cancer subtypesCancer Cell, 2006
- GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factorsNature Reviews Molecular Cell Biology, 2005
- CpG Islands in vertebrate genomesJournal of Molecular Biology, 1987